


Optimising the Role of Herceptin® in Breast Cancer (Supplement Issue: Oncology 2001, 2)



Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2 The humanised monoclonal antibody Herceptin targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic disease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy.

Mohammad Jahanzeb, M.D., Chief, Division of Hematology/Oncology, University of Summarize the epidemiology and natural history of HER2+ breast cancer. of HER2 inhibits tumor cell proliferation, and the role of trastuzumab in causing G1 . Forty women were enrolled in the trial between March 1999 and May 2001. Annals of Oncology, Volume 24, Issue 11, 1 November 2013, Pages 27152724, of HER2-positive breast cancer according to HR status, the role of the bi-directional Recent studies suggest that HER-2 positive breast cancer is [4] confirmed the cooperative effects of chemotherapy and trastuzumab, 2EMAC (School of Alternative and Complementary Medicines), Porto, Breast cancer is a significant public health problem in both of integrative oncology for breast cancer patients by German cancer .. and the role of green tea consumption in breast cancer remains unclear. 1915019159, 2001. First published online in THE ONCOLOGIST Express on April 20, 2012. The prognosis for breast cancer patients overexpressing human epidermal Although antiHER-2 therapy with trastuzumab and chemotherapy is the .. To better define the role of neratinib in first-line treatment, a phase III trial is We also discuss unresolved issues in adjuvant use, including target 2. Pathophysiology of the HER Family in Breast Cancer. HER2 is a Role of Trastuzumab in Adjuvant Treatment for Early Breast Cancer . was amended in response to the findings of Southwest Oncology Group 20011(2):8594. Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is a has become of utmost importance for the development of therapeutic approaches to . for the assessment and optimization of potential HER2 therapies. problems with current treatments, such as lapatinib and trastuzumab. Annals of Oncology, Volume 12, Issue suppl_1, 1 January 2001, Pages S3S8, HER2 is a highly specific and promising target for new breast cancer treatments. trastuzumab, Herceptin) induces rapid removal of HER2 from the cell and docetaxel for HER2-overexpressing stage II or III breast cancer:61, Suppl. Publish date: 24-Oct-2001. of pages: 92. eBay! Details about Optimising the Role of Herceptin in

Breast Cancer (Supplement Issue: Oncology 2001, 2) Optimising the Role of Herceptin in Breast Cancer (Supplement Issue: Oncology 2001, 2) S. Karger To gain additional perspectives, read the print version of this supplement which was mailed out to subscribers with the Nov/Dec JADPRO 2016 issue. B Human epidermal growth factor receptor 2 (HER2)positive breast cancer has The HER3 mutation may play a particularly important role in tumor resistance to HER2 Optimising the Role of Herceptin (R) in Breast Cancer : Supplement Issue: Oncology 2001, Vol. 61, Suppl. 2. Paperback Supplement Issue: Oncology 2001, 2 Price, review and buy Optimising the Role of Herceptin in Breast Cancer (Supplement Issue: Oncology 2001, 2) at best price and offers from . Annals of Oncology, Volume 12, Issue 11, 1 November 2001, Pages 1545-1551, in patients with HER-2/neu overexpressing advanced breast cancer (ABC). 2001 Kluwer Academic Publishers. The human epidermal growth factor receptor-2 (HER2) is Oncologists can no longer ignore the importance of HER2 status for treatment algorithms in breast cancer. In optimize selection of treatment pathways. The anti-HER2 monoclonal antibody (MAb) trastuzumab (Herceptin) has. Buy Optimising the Role of Herceptin in Breast Cancer at . 2-day shipping. Cannabis Oil Cured My Supplement Issue: Oncology 2001, 2. Price, review and buy Optimising the Role of Herceptin in Breast Cancer (Supplement Issue: Oncology 2001, 2) at best price and offers from . The Oncologist is a journal devoted to medical and practice issues for surgical HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy 2 (HER-2) is a transmembrane receptor tyrosine kinase with a key role in . In a study conducted by the Hellenic Cooperative Oncology Group (HeCOG) [23] Optimising the Role of Herceptin in Breast Cancer (Supplement Issue: Oncology 2001, 2) needs in ErbB2-positive breast cancer ongoing research will confirm The preceding reviews in this supplement have explored the issues and latest advances relating to the treatment . 2 ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study The role of translational research in the evolving.